Cardiogeni Company Description

Cardiogeni PLC, a clinical stage biotechnology company, develops heart failure medicines.

Its lead product is CLXR-001, a patented engineered cellular medicine, which has completed Phase II clinical trial to treat heart failure patients during coronary artery bypass grafting surgery.

The company also develops CLXR-002 and CLXR-003 for heart failure with minimally invasive delivery; and CLXR-004 for use in combination with LVAD device to treat sever heart failure orphan disease indication.

The company was founded in 2007 and is headquartered in Stratford-upon-Avon, the United Kingdom.

Cardiogeni PLC

Country	United Kingdom
Founded	2007
Industry	Biological Products, Except Diagnostic Substances
Employees	3
CEO	Trevor Reginald

Contact Details

Address: Celixir House Stratford-upon-Avon, CV37 7GZ United Kingdom
Website	cardiogeni.com

Stock Details

Ticker Symbol	CGNI
Exchange	Aquis Exchange
Fiscal Year	April - March
Reporting Currency	GBP
SIC Code	2836

Key Executives

Name	Position
Trevor Reginald	Chief Executive Officer
Sabena Sultan	Chief Operating Officer